Clinical
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
Summary
The phase 3 KEYLYNK-001 (ENGOT-OV43/GOG-3036) trial investigated the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance as first-line treatment for patients with advanced BRCA1/2 non-mutated epithelial ovarian cancer. The study randomized 1367 patients into three arms: pembrolizumab-olaparib, pembrolizumab alone, or placebo, all combined with initial chemotherapy. Results demonstrated a significant improvement in progression-free survival for the pembrolizumab-olaparib group compared to the control, both in the PD-L1 CPS ≥10 and intention-to-treat populations. This combination regimen suggests a potential new therapeutic option for this patient population.
Critical appraisal
This randomized, double-blind, placebo-controlled phase 3 trial provides high-level evidence for the efficacy of the pembrolizumab-olaparib combination as first-line treatment for advanced BRCA non-mutated ovarian cancer. The significant improvement in progression-free survival (HR 0.63 in the CPS ≥10 population and HR 0.68 in the ITT population at first analysis, maintained at HR 0.66 and HR 0.71 respectively at final analysis) is clinically meaningful. PD-L1 status (CPS ≥10) acts as a predictive biomarker, although benefit was also observed in the ITT population. These results could justify a change in clinical practice, offering a new treatment option for patients with newly diagnosed advanced BRCA non-mutated ovarian cancer. Clinical impact could be seen in the short-to-medium term (1-3 years), pending overall survival data.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology